Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

PubWeight™: 19.42‹?› | Rank: Top 0.1% | All-Time Top 10000

🔗 View Article (PMC 3157322)

Published in N Engl J Med on April 28, 2011

Authors

CATT Research Group, Daniel F Martin, Maureen G Maguire, Gui-shuang Ying, Juan E Grunwald, Stuart L Fine, Glenn J Jaffe

Associated clinical trials:

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial | NCT00593450

A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration | NCT00056836

A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration | NCT00061594

Study for Recalcitrant Age Related Macular Degeneration (TURF) | NCT01543568

Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases | NCT03128463

Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD (ARTIS) | NCT02810808

Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study) (VIBIM) | NCT02788877

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab (T-REX) | NCT01748292

Articles citing this

(truncated to the top 100)

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis (2012) 4.42

Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 3.85

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology (2013) 2.82

Mechanisms of age-related macular degeneration. Neuron (2012) 2.62

NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med (2012) 2.49

Cost-related motivations for conducting research: participants should be informed. JAMA (2014) 2.30

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology (2012) 2.19

Immunology of age-related macular degeneration. Nat Rev Immunol (2013) 2.14

Bimonthly injections of ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2014) 2.04

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.95

Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest (2012) 1.79

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.76

Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.73

Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.70

Ocular neovascularization. J Mol Med (Berl) (2013) 1.65

Stem cells in retinal regeneration: past, present and future. Development (2013) 1.59

Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 1.57

North Carolina Macular Dystrophy Is Caused by Dysregulation of the Retinal Transcription Factor PRDM13. Ophthalmology (2015) 1.55

Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov (2012) 1.52

Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review. Graefes Arch Clin Exp Ophthalmol (2012) 1.49

Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration. J Transl Med (2011) 1.47

The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc (2012) 1.46

Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye (Lond) (2014) 1.46

Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2014) 1.45

An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol (2012) 1.45

How can bedside rationing be justified despite coexisting inefficiency? The need for 'benchmarks of efficiency'. J Med Ethics (2012) 1.44

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol (2014) 1.41

Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol (2012) 1.40

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. PLoS One (2015) 1.40

The value of intraoperative optical coherence tomography imaging in vitreoretinal surgery. Curr Opin Ophthalmol (2014) 1.39

Animal models of age related macular degeneration. Mol Aspects Med (2012) 1.39

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One (2012) 1.38

Quantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography. Ophthalmology (2013) 1.35

Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab (2013) 1.34

A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol (2012) 1.33

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol (2014) 1.32

Cortical responses elicited by photovoltaic subretinal prostheses exhibit similarities to visually evoked potentials. Nat Commun (2013) 1.32

A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye (Lond) (2014) 1.30

Screening and Treatment in Retinopathy of Prematurity. Dtsch Arztebl Int (2015) 1.26

A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. Br J Ophthalmol (2014) 1.23

Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol (2012) 1.21

Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol (2014) 1.20

Autophagy activation clears ELAVL1/HuR-mediated accumulation of SQSTM1/p62 during proteasomal inhibition in human retinal pigment epithelial cells. PLoS One (2013) 1.20

Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol (2014) 1.20

NLRP3 inflammasome blockade inhibits VEGF-A-induced age-related macular degeneration. Cell Rep (2013) 1.18

The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review. BMJ (2012) 1.17

Anti-VEGF Treatment Strategies for Wet AMD. J Ophthalmol (2012) 1.17

What's fueling the biotech engine--2010 to 2011. Nat Biotechnol (2011) 1.17

Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog Retin Eye Res (2014) 1.17

Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol (2013) 1.16

Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2012) 1.15

Mechanism of inflammation in age-related macular degeneration. Mediators Inflamm (2012) 1.14

Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2012) 1.11

Drug-induced uveitis. J Ophthalmic Inflamm Infect (2013) 1.11

Insight into 144 patients with ocular vascular events during VEGF antagonist injections. Clin Ophthalmol (2012) 1.10

OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF TIME COURSE OF CHOROIDAL NEOVASCULARIZATION IN RESPONSE TO ANTI-ANGIOGENIC TREATMENT. Retina (2015) 1.09

Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf (2012) 1.08

Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy. Invest Ophthalmol Vis Sci (2013) 1.07

Combined depth imaging technique on spectral-domain optical coherence tomography. Am J Ophthalmol (2012) 1.07

Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 1.07

Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol (2012) 1.06

Ocriplasmin for vitreoretinal diseases. J Biomed Biotechnol (2012) 1.06

Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol (2012) 1.06

Bevacizumab versus ranibizumab for AMD. N Engl J Med (2011) 1.06

Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. Eye (Lond) (2011) 1.06

Management of retinal vascular diseases: a patient-centric approach. Eye (Lond) (2012) 1.05

Upregulation of CCR3 by age-related stresses promotes choroidal endothelial cell migration via VEGF-dependent and -independent signaling. Invest Ophthalmol Vis Sci (2011) 1.05

Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol (2013) 1.05

Ocular pharmacokinetics of bevacizumab in vitrectomized eyes with silicone oil tamponade. Invest Ophthalmol Vis Sci (2012) 1.04

Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 1.04

Aflibercept. Nat Rev Drug Discov (2012) 1.04

Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov (2016) 1.03

Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study. Int J Ophthalmol (2013) 1.03

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol (2013) 1.03

Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. J Ophthalmol (2011) 1.02

Medicare costs for neovascular age-related macular degeneration, 1994-2007. Am J Ophthalmol (2011) 1.02

Improving quality of life in patients with end-stage age-related macular degeneration: focus on miniature ocular implants. Clin Ophthalmol (2011) 1.02

Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye (Lond) (2014) 1.01

Cardiovascular, diabetes, and cancer strips: evidences, mechanisms, and classifications. J Thorac Dis (2014) 1.01

Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol (2014) 1.01

Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye. Trends Mol Med (2014) 1.00

Age-related macular degeneration-clinical review and genetics update. Clin Genet (2013) 1.00

Safe preparation and administration of intravitreal bevacizumab injections. N Engl J Med (2011) 1.00

Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br J Ophthalmol (2014) 1.00

Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ (2012) 1.00

Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye. Graefes Arch Clin Exp Ophthalmol (2012) 1.00

One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J Ophthalmol (2011) 0.99

A watertight acrylic-free titanium recording chamber for electrophysiology in behaving monkeys. J Neurophysiol (2011) 0.99

Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology (2014) 0.99

High-dose ranibizumab therapy for vascularized pigment epithelial detachment. Eye (Lond) (2012) 0.99

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Clin Interv Aging (2013) 0.99

Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD. Graefes Arch Clin Exp Ophthalmol (2011) 0.98

Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int (2014) 0.98

Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels. FASEB J (2014) 0.98

Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther (2013) 0.97

Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol (2012) 0.97

Antivascular endothelial growth factor agents for neovascular age-related macular degeneration. J Ophthalmol (2011) 0.97

Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clin Ophthalmol (2012) 0.97

Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci (2016) 0.97

Articles cited by this

Longitudinal data analysis for discrete and continuous outcomes. Biometrics (1986) 60.93

Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63

Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med (2006) 20.84

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ (1994) 17.35

New visual acuity charts for clinical research. Am J Ophthalmol (1982) 12.72

A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol (2003) 9.99

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology (2006) 9.01

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol (2007) 8.12

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging (2005) 7.31

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA (2008) 7.13

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol (2008) 5.22

Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol (2010) 4.50

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology (2009) 3.76

Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol (2011) 3.24

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology (2010) 3.22

Incorporation of clustering effects for the Wilcoxon rank sum test: a large-sample approach. Biometrics (2003) 2.49

Identifying and eliminating the roadblocks to comparative-effectiveness research. N Engl J Med (2010) 1.84

Articles by these authors

Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med (2008) 17.21

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91

Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 6.71

Comparison of preschool vision screening tests as administered by licensed eye care professionals in the Vision In Preschoolers Study. Ophthalmology (2004) 4.98

Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology (2006) 4.72

Evaluation of image artifact produced by optical coherence tomography of retinal pathology. Am J Ophthalmol (2005) 4.54

Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 3.85

Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol (2008) 3.14

Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol (2010) 2.96

Evaluation of artifacts associated with macular spectral-domain optical coherence tomography. Ophthalmology (2010) 2.92

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology (2013) 2.82

Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology (2007) 2.69

Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology (2012) 2.48

Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol (2007) 2.44

Darkness and near work: myopia and its progression in third-year law students. Ophthalmology (2002) 2.33

Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol (2003) 2.25

Retinal pigment epithelial changes after macular hole surgery with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol (2002) 2.20

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology (2012) 2.19

Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol (2007) 2.18

Utility of intraoperative optical coherence tomography during vitrectomy surgery for vitreomacular traction syndrome. Retina (2014) 2.15

Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology (2008) 2.10

Treatment choice for diabetic macular edema. N Engl J Med (2015) 2.06

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.95

Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures. Exp Eye Res (2005) 1.94

Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol (2009) 1.85

Identifying and eliminating the roadblocks to comparative-effectiveness research. N Engl J Med (2010) 1.84

In vivo human choroidal thickness measurements: evidence for diurnal fluctuations. Invest Ophthalmol Vis Sci (2008) 1.83

Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci (2005) 1.80

Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol (2011) 1.80

Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol (2013) 1.78

Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology (2009) 1.74

Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.73

Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.70

Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. Am J Ophthalmol (2006) 1.66

Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma. Am J Ophthalmol (2010) 1.66

Stereoacuity of preschool children with and without vision disorders. Optom Vis Sci (2014) 1.58

Retinopathy and cognitive impairment in adults with CKD. Am J Kidney Dis (2012) 1.58

Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 1.57

Incidence of exudative age-related macular degeneration among elderly Americans. Ophthalmology (2003) 1.54

Progression to severe retinopathy predicted by retinal vessel diameter between 31 and 34 weeks of postconception age. Arch Ophthalmol (2007) 1.52

Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema. Ophthalmology (2013) 1.51

Association of risk factors for choroidal neovascularization in age-related macular degeneration with decreased foveolar choroidal circulation. Am J Ophthalmol (2010) 1.47

Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A (2011) 1.47

Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. Ophthalmology (2009) 1.46

Comparison of spectral- and time-domain optical coherence tomography for retinal thickness measurements in healthy and diseased eyes. Am J Ophthalmol (2009) 1.39

Pathological findings in eyes with the ganciclovir implant. Ophthalmology (2005) 1.38

Effect of isometric exercise on choroidal blood flow in patients with age-related macular degeneration. Br J Ophthalmol (2010) 1.38

Reticular drusen associated with geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci (2011) 1.34

Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am J Ophthalmol (2013) 1.34

Early age-related maculopathy and self-reported visual difficulty in daily life. Ophthalmology (2002) 1.33

Foveolar choroidal hemodynamics in proliferative diabetic retinopathy. Int Ophthalmol (2004) 1.27

A clinical prediction model to stratify retinopathy of prematurity risk using postnatal weight gain. Pediatrics (2011) 1.23

Expression and modulation of RPE cell membrane complement regulatory proteins. Invest Ophthalmol Vis Sci (2009) 1.22

Oxidant-mediated Akt activation in human RPE cells. Invest Ophthalmol Vis Sci (2006) 1.21

Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis. Arch Neurol (2008) 1.20

Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol (2014) 1.20

Foveolar choroidal circulation and choroidal neovascularization in age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 1.18

Risk factors for choroidal neovascularization and vision loss in the fellow eye study of CNVPT. Retina (2003) 1.18

One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis. Am J Ophthalmol (2011) 1.17

Diurnal axial length fluctuations in human eyes. Invest Ophthalmol Vis Sci (2004) 1.16

Statin use and the incidence of advanced age-related macular degeneration in the Complications of Age-related Macular Degeneration Prevention Trial. Ophthalmology (2009) 1.13

A novel segmentation algorithm for volumetric analysis of macular hole boundaries identified with optical coherence tomography. Invest Ophthalmol Vis Sci (2013) 1.13

Uveitis in the elderly: epidemiological data from the National Long-term Care Survey Medicare Cohort. Ophthalmology (2006) 1.12

Primary intraocular lymphoma: clinical, cytologic, and flow cytometric analysis. Ophthalmology (2004) 1.11

Diffuse unilateral subacute neuroretinitis in Venezuela. Ophthalmology (2005) 1.09

Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. Ophthalmology (2011) 1.08

Semiautomated analysis of retinal vessel diameter in retinopathy of prematurity patients with and without plus disease. Am J Ophthalmol (2006) 1.07

Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol (2004) 1.06

Three cases of large retinal capillary hemangiomas treated with verteporfin and photodynamic therapy. Arch Ophthalmol (2005) 1.06

Is drusen area really so important? Invest Ophthalmol Vis Sci (2012) 1.06

Fully automatic software for retinal thickness in eyes with diabetic macular edema from images acquired by cirrus and spectralis systems. Invest Ophthalmol Vis Sci (2013) 1.06

Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol (2007) 1.03

Current knowledge and trends in age-related macular degeneration: today's and future treatments. Retina (2013) 1.02

Topography of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci (2012) 1.02

Automated combined kinetic and static perimetry: an alternative to standard perimetry in patients with neuro-ophthalmic disease and glaucoma. Arch Ophthalmol (2006) 1.02

Highly precise eye length measurements in children aged 3 through 12 years. Arch Ophthalmol (2003) 1.02

Semiautomated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci (2011) 1.01

Iron levels in human retina: sex difference and increase with age. Neuroreport (2006) 1.01

Optical coherence tomography reader agreement in neovascular age-related macular degeneration. Am J Ophthalmol (2007) 1.00

Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). Retina (2009) 0.99

Macular pigment and lutein supplementation in choroideremia. Exp Eye Res (2002) 0.98